Abhimanyu Garg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1057602/publications.pdf

Version: 2024-02-01

164 papers	16,508 citations	16451 64 h-index	15266 126 g-index
168 all docs	168 docs citations	168 times ranked	11349 citing authors

#	Article	IF	Citations
1	Lipodystrophy for the Diabetologistâ€"What to Look For. Current Diabetes Reports, 2022, 22, 461-470.	4.2	12
2	Severe Liver Injury Associated With High-Dose Atorvastatin Therapy. Journal of Investigative Medicine High Impact Case Reports, 2021, 9, 232470962110140.	0.6	7
3	Genetic Lipodystrophies. , 2021, , 25-48.		0
4	Diet-Responsive Hypercholesterolemia With Cardiofaciocutaneous Syndrome Type 3. Journal of the Endocrine Society, 2021, 5, A308-A308.	0.2	0
5	Approach to Diagnosing a Pediatric Patient With Severe Insulin Resistance in Low- or Middle-income Countries. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3621-3633.	3.6	1
6	Decreased caveolae in AGPAT2 lacking adipocytes is independent of changes in cholesterol or sphingolipid levels: A whole cell and plasma membrane lipidomic analysis of adipogenesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166167.	3.8	5
7	Lipodystrophies. Contemporary Cardiology, 2021, , 417-429.	0.1	0
8	A novel autosomal recessive lipodystrophy syndrome due to homozygous LMNA variant. Journal of Medical Genetics, 2020, 57, 422-426.	3.2	4
9	Multisystem Progeroid Syndrome With Lipodystrophy, Cardiomyopathy, and Nephropathy Due to an LMNA p.R349W Variant. Journal of the Endocrine Society, 2020, 4, bvaa104.	0.2	7
10	A Novel Syndrome With Short Stature, Mandibular Hypoplasia, and Osteoporosis May Be Associated With a PRRT3 Variant. Journal of the Endocrine Society, 2020, 4, bvaa088.	0.2	0
11	Absence of AGPAT2 impairs brown adipogenesis, increases IFN stimulated gene expression and alters mitochondrial morphology. Metabolism: Clinical and Experimental, 2020, 111, 154341.	3.4	14
12	Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2132-2141.	3.6	11
13	Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort. Journal of the Endocrine Society, 2020, 4, bvz015.	0.2	10
14	SUN-LB111 Comparison of Phenotype and Metabolic Abnormalities Among Familial Partial Lipodystrophy Due to LMNA or PPARG Variants. Journal of the Endocrine Society, 2020, 4, .	0.2	1
15	SAT-572 Extremely Elevated Plasma Lipoprotein X Level Secondary to Alcoholic Cholestasis. Journal of the Endocrine Society, 2020, 4, .	0.2	0
16	Very Severe Hypertriglyceridemia in a Large US County Health Care System: Associated Conditions and Management. Journal of the Endocrine Society, 2019, 3, 1595-1607.	0.2	22
17	Insights into lipid accumulation in skeletal muscle in dysferlin-deficient mice. Journal of Lipid Research, 2019, 60, 2057-2073.	4.2	11
18	Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3068-3076.	3.6	26

#	Article	IF	Citations
19	The relationships between macronutrient and micronutrient intakes and type 2 diabetes mellitus in South Asians: A review. Journal of Diabetes and Its Complications, 2019, 33, 500-507.	2.3	5
20	Postmortem Findings in a Young Man With Congenital Generalized Lipodystrophy, Type 4 Due to CAVIN1 Mutations. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 957-960.	3.6	12
21	Regional Body Fat Changes and Metabolic Complications in Children With Dunnigan Lipodystrophy-Causing LMNA Variants. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1099-1108.	3.6	27
22	Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease. Pathology, 2019, 51, 202-212.	0.6	67
23	SUN-135 Dual Energy X-Ray Absorptiometry (DEXA) as a Diagnostic Tool for Familial Partial Lipodystrophy, Dunnigan Variety (FPLD2). Journal of the Endocrine Society, 2019, 3, .	0.2	0
24	A novel paraneoplastic syndrome with acquired lipodystrophy and chronic inflammatory demyelinating polyneuropathy in an adolescent male with craniopharyngioma. Journal of Pediatric Endocrinology and Metabolism, 2018, 31, 479-483.	0.9	3
25	The prevalence and etiology of extreme hypertriglyceridemia in children: Data from a tertiary children's hospital. Journal of Clinical Lipidology, 2018, 12, 305-310.	1.5	20
26	Comparison of nutrient intakes in South Asians with type 2 diabetes mellitus and controls living in the United States. Diabetes Research and Clinical Practice, 2018, 138, 47-56.	2.8	13
27	A Novel Generalized Lipodystrophy-Associated Progeroid Syndrome Due to Recurrent Heterozygous LMNA p.T10I Mutation. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1005-1014.	3.6	47
28	Compound heterozygous familial hypercholesterolemia in a Chinese boy with a deÂnovo and transmitted low-density lipoprotein receptor mutation. Journal of Clinical Lipidology, 2018, 12, 230-235.e6.	1.5	8
29	Bi-allelic POLR3A Loss-of-Function Variants Cause Autosomal-Recessive Wiedemann-Rautenstrauch Syndrome. American Journal of Human Genetics, 2018, 103, 968-975.	6.2	43
30	Orlistat Therapy for Children With Type 1 Hyperlipoproteinemia: A Randomized Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2403-2407.	3.6	13
31	Efficacy and Safety of Metreleptin Therapy in Patients With Type 1 Diabetes: A Pilot Study. Diabetes Care, 2017, 40, 694-697.	8.6	29
32	Progeroid syndrome patients with ZMPSTE24 deficiency could benefit when treated with rapamycin and dimethylsulfoxide. Journal of Physical Education and Sports Management, 2017, 3, a001339.	1.2	9
33	Extreme hypertriglyceridemia, pseudohyponatremia, and pseudoacidosis in a neonate with lipoprotein lipase deficiency due to segmental uniparental disomy. Journal of Clinical Lipidology, 2017, 11, 757-762.	1.5	14
34	Heterozygous Null LDLR Mutation in a Familial Hypercholesterolemia Patient With an Atypical Presentation Because of Alcohol Abuse. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	3
35	Juvenileâ€onset generalized lipodystrophy due to a novel heterozygous missense LMNA mutation affecting lamin C. American Journal of Medical Genetics, Part A, 2017, 173, 2517-2521.	1.2	17
36	Metabolic, Reproductive, and Neurologic Abnormalities in Agpat1-Null Mice. Endocrinology, 2017, 158, 3954-3973.	2.8	20

#	Article	IF	Citations
37	Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy. American Journal of Medical Genetics, Part A, 2017, 173, 190-194.	1.2	41
38	Activation of Sphingolipid Pathway in the Livers of Lipodystrophic Agpat2â^'/â^' Mice. Journal of the Endocrine Society, 2017, 1, 980-993.	0.2	5
39	Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 375-383.	2.4	85
40	Seipin is required for converting nascent to mature lipid droplets. ELife, 2016, 5, .	6.0	292
41	Lipodystrophies. , 2016, , 325-339.		2
42	JCL roundtable: Diagnosis and clinical management of lipodystrophy. Journal of Clinical Lipidology, 2016, 10, 728-736.	1.5	6
43	AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue. Molecular Metabolism, 2016, 5, 491-505.	6.5	36
44	Spectrum of clinical manifestations in two young Turkish patients with congenital generalized lipodystrophy type 4. European Journal of Medical Genetics, 2016, 59, 320-324.	1.3	23
45	The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4500-4511.	3.6	323
46	Type 1 Hyperlipoproteinemia Due to Compound Heterozygous Rare Variants in GCKR. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3884-3887.	3.6	9
47	Lipodystrophy Syndromes. Endocrinology and Metabolism Clinics of North America, 2016, 45, 783-797.	3.2	133
48	Natural History of Congenital Generalized Lipodystrophy: A Nationwide Study From Turkey. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2759-2767.	3.6	67
49	Type 1 hyperlipoproteinemia in a child with large homozygous deletion encompassing GPIHBP1. Journal of Clinical Lipidology, 2016, 10, 1035-1039.e2.	1.5	16
50	Premature coronary heart disease and autosomal dominant hypercholesterolemia: Increased risk in women with LDLR mutations. Journal of Clinical Lipidology, 2016, 10, 101-108.e3.	1.5	19
51	Mogat1 deletion does not ameliorate hepatic steatosis in lipodystrophic (Agpat2â^'/â^') or obese (ob/ob) mice. Journal of Lipid Research, 2016, 57, 616-630.	4.2	29
52	Whole-exome sequencing identifies ADRA2A mutation in atypical familial partial lipodystrophy. JCI Insight, 2016, 1, .	5.0	23
53	Characterization of the Mouse and Human Monoacylglycerol O-Acyltransferase 1 (Mogat1) Promoter in Human Kidney Proximal Tubule and Rat Liver Cells. PLoS ONE, 2016, 11, e0162504.	2.5	13
54	Whole exome sequencing identifies de novo heterozygous CAV1 mutations associated with a novel neonatal onset lipodystrophy syndrome. American Journal of Medical Genetics, Part A, 2015, 167, 1796-1806.	1.2	71

#	Article	IF	Citations
55	Lipodystrophies and Dyslipidemias. Contemporary Endocrinology, 2015, , 287-302.	0.1	0
56	Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy. Journal of Clinical Lipidology, 2015, 9, 832-836.	1.5	6
57	Congenital generalized lipodystrophiesâ€"new insights into metabolic dysfunction. Nature Reviews Endocrinology, 2015, 11, 522-534.	9.6	195
58	Novel Lipid-Lowering Agents. Contemporary Endocrinology, 2015, , 499-519.	0.1	0
59	A Novel Syndrome of Generalized Lipodystrophy Associated With Pilocytic Astrocytoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3603-3606.	3.6	21
60	Extreme hypercholesterolemia presenting with pseudohyponatremia - a case report and review of the literature. Journal of Clinical Lipidology, 2015, 9, 260-264.	1.5	31
61	De novo heterozygous FBN1 mutations in the extreme Câ€terminal region cause progeroid fibrillinopathy. American Journal of Medical Genetics, Part A, 2014, 164, 1341-1345.	1.2	19
62	Hepatic Gluconeogenesis Is Enhanced by Phosphatidic Acid Which Remains Uninhibited by Insulin in Lipodystrophic Agpat2â^'/â^' Mice. Journal of Biological Chemistry, 2014, 289, 4762-4777.	3.4	17
63	Genotype-phenotype relationships in patients with type I hyperlipoproteinemia. Journal of Clinical Lipidology, 2014, 8, 287-295.	1.5	54
64	Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2 lipodystrophic mice independent of hepatocyte leptin receptors. Journal of Lipid Research, 2014, 55, 276-288.	4.2	43
65	Eruptive Xanthomas Masquerading as Molluscum Contagiosum. Pediatrics, 2014, 134, e257-e260.	2.1	4
66	Abstract 20361: Statin-Induced Myopathy in Patients With Familial Hypercholesterolemia. Circulation, 2014, 130, .	1.6	0
67	Genetic Lipodystrophies. , 2013, , 1-16.		1
68	Cardiac Steatosis and Left Ventricular Hypertrophy in Patients WithÂGeneralized Lipodystrophy as Determined by Magnetic Resonance Spectroscopy and Imaging. American Journal of Cardiology, 2013, 112, 1019-1024.	1.6	59
69	Increased Skeletal Muscle Volume in Women With Familial Partial Lipodystrophy, Dunnigan Variety. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1410-E1413.	3.6	29
70	Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial. European Journal of Endocrinology, 2013, 168, 771-778.	3.7	15
71	The Effect of Dietary Counseling on Nutrient Intakes in Gastric Banding Surgery Patients. Journal of Investigative Medicine, 2013, 61, 1165-1172.	1.6	5
72	The Clinical Approach to the Detection of Lipodystrophy an Aace Consensus Statement. Endocrine Practice, 2013, 19, 107-116.	2.1	83

#	Article	IF	Citations
73	Comparison of Efficacy and Safety of Leptin Replacement Therapy in Moderately and Severely Hypoleptinemic Patients with Familial Partial Lipodystrophy of the Dunnigan Variety. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 785-792.	3.6	80
74	Low Prevalence of Mutations in Known Loci for Autosomal Dominant Hypercholesterolemia in a Multiethnic Patient Cohort. Circulation: Cardiovascular Genetics, 2012, 5, 666-675.	5.1	51
75	Deletion of GPIHBP1 causing severe chylomicronemia. Journal of Inherited Metabolic Disease, 2012, 35, 531-540.	3.6	80
76	A unique model for evaluating obesity cardiomyopathy: Can less mean more?. FASEB Journal, 2012, 26, 877.3.	0.5	0
77	Lipodystrophies: Genetic and Acquired Body Fat Disorders. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3313-3325.	3.6	434
78	Total reversal of weight loss from adjustable gastric banding surgery associated with excessive intake of energy dense liquid and solid foods: A case report. Obesity Research and Clinical Practice, 2011, 5, e65-e69.	1.8	0
79	Highâ€Volume Exercise Program in Obese Bariatric Surgery Patients: A Randomized, Controlled Trial. Obesity, 2011, 19, 1826-1834.	3.0	122
80	What is the role of alternative biomarkers for coronary heart disease?. Clinical Endocrinology, 2011, 75, 289-293.	2.4	7
81	Human 1-Acylglycerol-3-phosphate O-Acyltransferase Isoforms 1 and 2. Journal of Biological Chemistry, 2011, 286, 37676-37691.	3.4	82
82	Type 1 Hyperlipoproteinemia and Recurrent Acute Pancreatitis due to Lipoprotein Lipase Antibody in a Young Girl with SjÃ¶gren's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3302-3307.	3.6	23
83	The Effect of Dietary Counseling on Nutrient Intakes in Bariatric Surgery Patients. FASEB Journal, 2011, 25, .	0.5	0
84	PSMB8 Encoding the Î²5i Proteasome Subunit Is Mutated in Joint Contractures, Muscle Atrophy, Microcytic Anemia, and Panniculitis-Induced Lipodystrophy Syndrome. American Journal of Human Genetics, 2010, 87, 866-872.	6.2	305
85	Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. American Journal of Medical Genetics, Part A, 2010, 152A, 2245-2253.	1.2	112
86	Early onset mandibuloacral dysplasia due to compound heterozygous mutations in ZMPSTE24. American Journal of Medical Genetics, Part A, 2010, 152A, 2703-2710.	1.2	45
87	Enzymatic activity of the human 1-acylglycerol-3-phosphate-O-acyltransferase isoform 11: upregulated in breast and cervical cancers. Journal of Lipid Research, 2010, 51, 2143-2152.	4.2	46
88	A Novel Syndrome of Mandibular Hypoplasia, Deafness, and Progeroid Features Associated with Lipodystrophy, Undescended Testes, and Male Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E192-E197.	3.6	56
89	An Autosomal Recessive Syndrome of Joint Contractures, Muscular Atrophy, Microcytic Anemia, and Panniculitis-Associated Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E58-E63.	3.6	88
90	High volume cardiorespiratory endurance exercise (CREE) improves physical fitness in obese bariatric surgery patients in a randomized controlled trial. FASEB Journal, 2010, 24, 95.3.	0.5	0

#	Article	IF	Citations
91	Atypical Progeroid Syndrome due to Heterozygous Missense LMNA Mutations. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4971-4983.	3.6	113
92	Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Molecular Medicine, 2009, 1, 280-287.	6.9	235
93	Molecular Mechanisms of Hepatic Steatosis and Insulin Resistance in the AGPAT2-Deficient Mouse Model of Congenital Generalized Lipodystrophy. Cell Metabolism, 2009, 9, 165-176.	16.2	206
94	Lipodystrophies: Disorders of adipose tissue biology. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 507-513.	2.4	153
95	Lipodystrophy. Obstetrics and Gynecology, 2009, 114, 427-431.	2.4	12
96	Inherited lipodystrophies and hypertriglyceridemia. Current Opinion in Lipidology, 2009, 20, 300-308.	2.7	52
97	Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability. American Journal of Medical Genetics, Part A, 2008, 146A, 2318-2326.	1.2	43
98	Severe Mandibuloacral Dysplasia-Associated Lipodystrophy and Progeria in a Young Girl with a Novel Homozygous Arg527Cys LMNA Mutation. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4617-4623.	3.6	50
99	Blepharoptosis and External Ophthalmoplegia Associated with Longâ€Term Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 47, 845-852.	5.8	19
100	Caveolin-1: A New Locus for Human Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1183-1185.	3.6	44
101	Atypical Forms of Type 2 Diabetes. , 2008, , 413-431.		0
102	The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20890-20895.	7.1	530
103	Functional characterization of human 1-acylglycerol-3-phosphate-O-acyltransferase isoform 9: cloning, tissue distribution, gene structure, and enzymatic activity. Journal of Endocrinology, 2007, 193, 445-457.	2.6	45
104	Mislocalization of prelamin A Tyr646Phe mutant to the nuclear pore complex in human embryonic kidney 293 cells. Biochemical and Biophysical Research Communications, 2007, 355, 78-84.	2.1	16
105	Update on Dyslipidemia. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1581-1589.	3.6	102
106	The Ongoing Saga of Obestatin: Is It a Hormone?. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3396-3398.	3.6	34
107	Body fat distribution and metabolic variables in patients with neonatal progeroid syndrome. American Journal of Medical Genetics, Part A, 2007, 143A, 1421-1430.	1.2	33
108	Genetic Disorders of Adipose Tissue Development, Differentiation, and Death. Annual Review of Genomics and Human Genetics, 2006, 7, 175-199.	6.2	137

#	Article	IF	Citations
109	Functional characterization of human 1-acylglycerol-3-phosphate acyltransferase isoform 8: Cloning, tissue distribution, gene structure, and enzymatic activity. Archives of Biochemistry and Biophysics, 2006, 449, 64-76.	3.0	58
110	Laminopathies: Multisystem dystrophy syndromes. Molecular Genetics and Metabolism, 2006, 87, 289-302.	1.1	104
111	Focal Segmental Glomerulosclerosis in Patients with Mandibuloacral Dysplasia Owing to ZMPSTE24 Deficiency. Journal of Investigative Medicine, 2006, 54, 208-213.	1.6	60
112	Lipodystrophy: lessons in lipid and energy metabolism. Current Opinion in Lipidology, 2006, 17, 162-169.	2.7	97
113	Adipose tissue dysfunction in obesity and lipodystrophy. Clinical Cornerstone, 2006, 8, S7-S13.	0.7	65
114	A Homozygous Mutation in the Lamin A/C Gene Associated with a Novel Syndrome of Arthropathy, Tendinous Calcinosis, and Progeroid Features. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 517-521.	3.6	36
115	Long-Term Impact of Bariatric Surgery on Body Weight, Comorbidities, and Nutritional Status. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4223-4231.	3.6	368
116	Genetic Basis of Lipodystrophies and Management of Metabolic Complications. Annual Review of Medicine, 2006, 57, 297-311.	12.2	134
117	Phenotypic Heterogeneity in Body Fat Distribution in Patients with Atypical Wernerâ€™s Syndrome Due to Heterozygous Arg133Leu Lamin A/C Mutation. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6699-6706.	3.6	32
118	A Novel Homozygous Ala529ValLMNAMutation in Turkish Patients with Mandibuloacral Dysplasia. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5259-5264.	3.6	58
119	Enzymatic activity of naturally occurring 1-acylglycerol-3-phosphate-O-acyltransferase 2 mutants associated with congenital generalized lipodystrophy. Biochemical and Biophysical Research Communications, 2005, 327, 446-453.	2.1	52
120	Mutations in the Seipin and AGPAT2 Genes Clustering in Consanguineous Families with Berardinelli-Seip Congenital Lipodystrophy from Two Separate Geographical Regions of Brazil. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 357-361.	3.6	38
121	Regional Adiposity and Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4206-4210.	3.6	167
122	Acquired and Inherited Lipodystrophies. New England Journal of Medicine, 2004, 350, 1220-1234.	27.0	811
123	Adipocyte biology and adipocytokines. Clinics in Laboratory Medicine, 2004, 24, 217-234.	1.4	23
124	Lipodystrophies: rare disorders causing metabolic syndrome. Endocrinology and Metabolism Clinics of North America, 2004, 33, 305-331.	3.2	119
125	Seipin: a mysterious protein. Trends in Molecular Medicine, 2004, 10, 440-444.	6.7	70
126	Statins for all patients with type 2 diabetes: not so soon. Lancet, The, 2004, 364, 641-642.	13.7	37

#	Article	IF	Citations
127	Clinical Features and Metabolic and Autoimmune Derangements in Acquired Partial Lipodystrophy. Medicine (United States), 2004, 83, 18-34.	1.0	234
128	LMNA mutations in atypical Werner's syndrome. Lancet, The, 2003, 362, 440-445.	13.7	397
129	Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways. Trends in Endocrinology and Metabolism, 2003, 14, 214-221.	7.1	147
130	Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Human Molecular Genetics, 2003, 12, 1995-2001.	2.9	351
131	Effect of Leptin Replacement on Intrahepatic and Intramyocellular Lipid Content in Patients With Generalized Lipodystrophy. Diabetes Care, 2003, 26, 30-35.	8.6	115
132	Risk Factors for Diabetes in Familial Partial Lipodystrophy, Dunnigan Variety. Diabetes Care, 2003, 26, 1350-1355.	8.6	68
133	Phenotypic and Genetic Heterogeneity in Congenital Generalized Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4840-4847.	3.6	217
134	Genetic and Phenotypic Heterogeneity in Patients with Mandibuloacral Dysplasia-Associated Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2821-2824.	3.6	120
135	Phenotypic Heterogeneity in Body Fat Distribution in Patients with Congenital Generalized Lipodystrophy Caused by Mutations in the AGPAT2 or Seipin Genes. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5433-5437.	3.6	155
136	Clinical Features and Metabolic Derangements in Acquired Generalized Lipodystrophy. Medicine (United States), 2003, 82, 129-146.	1.0	194
137	Lipodystrophy in Human Immunodeficiency Virus-Infected Patients. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4845-4856.	3.6	202
138	Hepatic Steatosis, Insulin Resistance, and Adipose Tissue Disorders. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3019-3022.	3.6	114
139	Body Fat Distribution and Metabolic Derangements in Patients with Familial Partial Lipodystrophy Associated with Mandibuloacral Dysplasia. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 776-785.	3.6	107
140	Serum Adiponectin and Leptin Levels in Patients with Lipodystrophies. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2395-2395.	3.6	307
141	A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor-Î³ Gene in a Patient with Familial Partial Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 408-408.	3.6	234
142	Multisystem dystrophy syndrome due to novel missense mutations in the amino-terminal head and alpha-helical rod domains of the lamin A/C gene. American Journal of Medicine, 2002, 112, 549-555.	1.5	138
143	Leptin-Replacement Therapy for Lipodystrophy. New England Journal of Medicine, 2002, 346, 570-578.	27.0	1,130
144	The effect of dietary intervention on serum lipid levels in type 2 diabetes mellitus. Current Diabetes Reports, 2002, 2, 289-294.	4.2	3

#	Article	IF	Citations
145	AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nature Genetics, 2002, 31, 21-23.	21.4	475
146	Body Fat Distribution and Metabolic Derangements in Patients with Familial Partial Lipodystrophy Associated with Mandibuloacral Dysplasia. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 776-785.	3.6	33
147	Serum Adiponectin and Leptin Levels in Patients with Lipodystrophies. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2395-2395.	3.6	92
148	Hepatic Steatosis, Insulin Resistance, and Adipose Tissue Disorders. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3019-3022.	3.6	45
149	Phenotypic Heterogeneity in Patients with Familial Partial Lipodystrophy (Dunnigan Variety) Related to the Site of Missense Mutations in Lamin A/C Gene1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 59-65.	3.6	97
150	Gender Differences in the Prevalence of Metabolic Complications in Familial Partial Lipodystrophy (Dunnigan Variety)*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1776-1782.	3.6	139
151	Lipodystrophies. American Journal of Medicine, 2000, 108, 143-152.	1.5	425
152	Mutational and Haplotype Analyses of Families with Familial Partial Lipodystrophy (Dunnigan Variety) Reveal Recurrent Missense Mutations in the Globular C-Terminal Domain of Lamin A/C. American Journal of Human Genetics, 2000, 66, 1192-1198.	6.2	260
153	Beneficial Effects of High Dietary Fiber Intake in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 2000, 342, 1392-1398.	27.0	899
154	A Gene for Congenital Generalized Lipodystrophy Maps to Human Chromosome 9q34. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3390-3394.	3.6	167
155	Adipose Tissue Distribution Pattern in Patients with Familial Partial Lipodystrophy (Dunnigan Variety)1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 170-174.	3.6	173
156	Monogenic disorders of obesity and body fat distribution. Journal of Lipid Research, 1999, 40, 1735-1746.	4.2	41
157	Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21â€“22. Nature Genetics, 1998, 18, 292-295.	21.4	151
158	Serum low-density lipoprotein cholesterol response to modification of saturated fat intake: recent insights. Current Opinion in Lipidology, 1997, 8, 332-336.	2.7	8
159	Relationship of Anterior and Posterior Subcutaneous Abdominal Fat to Insulin Sensitivity in Nondiabetic Men. Obesity, 1997, 5, 93-99.	4.0	178
160	Heterogeneity in adipose tissue metabolism: Causes, implications and management of regional adiposity. Progress in Lipid Research, 1995, 34, 53-70.	11.6	79
161	Effects of Varying Carbohydrate Content of Diet in Patients With Nonâ€”Insulin-Dependent Diabetes Mellitus. JAMA - Journal of the American Medical Association, 1994, 271, 1421.	7.4	289
162	Nicotinic Acid as Therapy for Dyslipidemia in Nonâ€”Insulin-Dependent Diabetes Mellitus. JAMA - Journal of the American Medical Association, 1990, 264, 723.	7.4	219

#	Article	IF	Citations
163	Lovastatin for Lowering Cholesterol Levels in Non-Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 1988, 318, 81-86.	27.0	176
164	Comparison of a High-Carbohydrate Diet with a High-Monounsaturated-Fat Diet in Patients with Non-Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 1988, 319, 829-834.	27.0	383